Sequential Response to FGFR3 Inhibition With Subsequent Exceptional Response to Atezolizumab in a Patient With FGFR3-TACC3 Fusion-Positive Metastatic Urothelial Carcinoma
1 and , Brigham and Women's Hospital, Harvard Medical School; , , , and , Dana Farber Cancer Institute; and , The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA.